Pharmaceutical Technology

APRIL 25, 2024

A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.

Drug Pricing 52

Drug Pricing Diabetes 52

STAT

AUGUST 10, 2023

The company is riding a wave of sky-high demand for its highly effective diabetes and weight-loss drugs, Ozempic and Wegovy, but will extend the limits introduced for Wegovy supplies.  The news came as the drugmaker raised its full-year profit and sales forecasts for a second time.

Drug Pricing 178

Drug Pricing Diabetes 178

STAT

MARCH 29, 2024

Diabetes drugs are too expensive in the U.S., And blockbuster GLP-1 drugs, too, could be a lot less expensive, according to an investigation published this week in JAMA Network Open, with a simple change: robust generic competition. based on an estimate that factors in a 10% to 50% profit margin.

Diabetes 334

Diabetes Drug Pricing 334

pharmaphorum

NOVEMBER 21, 2022

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. It also has an option on global marketing rights to the drug.

Diabetes 116

Diabetes Drug Pricing 116

STAT

NOVEMBER 8, 2023

Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market.

Diabetes 363

Diabetes Drug Pricing 363

STAT

MAY 23, 2023

… Novo Nordisk disclosed that an oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity , STAT writes. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Drug Pricing 193

Drug Pricing Dosage Diabetes 193

STAT

DECEMBER 6, 2023

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering.

Diabetes 248

Diabetes Drug Pricing 248

STAT

MARCH 15, 2024

Final approval will be contingent on the results of an ongoing study designed to show the drug can improve long-term outcomes for patients. Beyond that timeframe, though, Moody’s expects the prescription drug pricing provisions in the Inflation Reduction Act will more significantly constrain industry growth.

Drug Pricing 178

Drug Pricing Biosimilars Diabetes 178

STAT

MAY 9, 2023

Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. But it will be a show.

Drug Pricing 221

Drug Pricing Diabetes 221

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 183

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 183

Express Pharma

APRIL 22, 2024

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. billion in 2024, according to GlobalData’s Drugs Database Pharma Intelligence Center.

Drug Pricing 97

Drug Pricing Diabetes Vaccines 97

STAT

OCTOBER 24, 2023

… European authorities asked four companies, including Novo Nordisk and Eli Lilly, to provide more information about possible anesthesia complications from weight-loss and diabetes drugs , Bloomberg News says. government over drug pricing, The Financial Times reports.

Drug Pricing 205

Drug Pricing Diabetes 205

STAT

MARCH 14, 2023

list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.

Diabetes 240

Diabetes Drug Pricing 240

Express Pharma

FEBRUARY 21, 2024

The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug price negotiations under the Inflation Reduction Act (IRA). Nonetheless, there was a resilient upturn of 1.6

Drug Pricing 83

Drug Pricing Diabetes Biosimilars 83

STAT

DECEMBER 15, 2022

For people in marginalized and traditionally underserved communities, in which chronic medical conditions such as diabetes, obesity, and respiratory diseases are more widespread, the problem can be the difference between life and death. And for some new medications, it seems the sky’s the limit when it comes to cost.

Diabetes 199

Diabetes Drug Pricing 199

STAT

APRIL 12, 2024

Food and Drug Administration, which in January said it did not find a causal relationship between the class of weight loss and diabetes medications and suicidal ideation. The  The announcement from the European Medicines Agency echoes the findings of a review by the U.S.

Drug Development 177

Drug Development Diabetes Drug Pricing 177

Digital Pharmacist

MARCH 19, 2024

From sweeping federal legislation aimed at reigning in costs to the unexpected maneuvers of drug manufacturers, the effects of these changes reverberate throughout the healthcare system. The Dynamics of Increasing Drug Prices The escalation of drug prices is a multifaceted issue, with various factors contributing to its rise.

Drug Pricing 52

Drug Pricing Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

STAT

DECEMBER 15, 2022

In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.

Diabetes 205

Diabetes Drug Pricing 205

STAT

NOVEMBER 16, 2022

After a tweet from a fake corporate account last week claimed Eli Lilly would give insulin away for free, the drugmaker’s chief executive officer acknowledged the need to do a better job of widening access to the life-saving diabetes treatment and change perceptions of its existing efforts to do so.

Diabetes 224

Diabetes Drug Pricing 224

STAT

SEPTEMBER 23, 2022

These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. As I write this, there are 38 FDA-approved biosimilars ; 22 of them are commercially available. According to the most recent “U.S.

Biosimilars 201

Biosimilars Diabetes Drug Pricing 201

STAT

JULY 6, 2023

Advertisements eviscerating and glorifying pharmacy benefit managers have been around for years, but have intensified over the past three months as Congress scrutinizes the role these middlemen play in shaping high prescription drug prices , STAT tells us.

Drug Pricing 151

Drug Pricing Vaccines Diabetes Pharmaceutical Companies 151

STAT

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Drug Pricing 161

Drug Pricing Diabetes 161

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The company is expected to continue experiencing positive growth from its new immunology drugs, Skyrizi (risankizumab-rzaa) and Rinvoq (upadacitinib).

Vaccines 52

Vaccines Diabetes Drug Pricing Biosimilars 52

Express Pharma

SEPTEMBER 6, 2023

According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes. The post Is India capable of ensuring equitable access to biopharmaceuticals?

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Pharmaceutical Technology

MAY 16, 2023

increase in market capitalisation over Q1 2023, fuelled by its robust portfolio of diabetes and obesity treatments – in particular, its line of glucagon-like peptide 1 receptor agonist (GLP-1) Type 2 diabetes drugs Ozempic, Rybelsus and Victoza. Novo Nordisk reported an 18.2%

Diabetes 52

Diabetes Vaccines Drug Pricing 52

STAT

MAY 9, 2023

plan to negotiate drug prices for its Medicare health coverage, including the argument that a ban against speaking about these talks violates constitutional rights , Reuters reports. We enjoy hearing your secrets … Some of the world’s biggest drugmakers are laying legal groundwork to fight the U.S.

Drug Pricing 207

Drug Pricing Diabetes 207

pharmaphorum

APRIL 27, 2022

Working on a diabetes drug? Look at how your drug pricing and access impact certain demographics and then work from there. Pharma teams should pick a few issues to focus on, rather than trying to “fix” everything at once. Choose something that relates to your brand(s) or team. Working in the respiratory field?

Vaccines 98

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 98

STAT

JUNE 19, 2023

… Bristol Myers Squibb sued the Biden administration over the new powers given Medicare to negotiate drug prices, the third such lawsuit to be filed against the program in a matter of days , CNBC says, The lawsuit argues that the planned Medicare negotiations violate the First and Fifth Amendments of the U.S.

Diabetes 216

Diabetes Drug Pricing 216

STAT

APRIL 30, 2024

Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for asthma, COPD, diabetes and weight loss, including the blockbuster Ozempic diabetes medicine sold by Novo Nordisk.

Diabetes 177

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 177

pharmaphorum

JANUARY 28, 2021

Up until now, the insulin market has experienced little competition and, as a result, prices have soared over the years. More than 30 million Americans have diabetes and another 88 million are at risk of developing it. One of these markets is the insulin market.

Biosimilars 111

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 111

STAT

NOVEMBER 9, 2023

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

Diabetes 211

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 211

Proxsys Rx

MAY 18, 2023

The skyrocketing costs of prescription drugs It’s no secret that prescription drug prices are rising faster than the rate of inflation, forcing employers to shift more of their prescription benefit costs to their employees and families. This usually means higher deductibles, higher co-pays, and lower morale among employees.

Drug Pricing 52

Drug Pricing Dosage Diabetes 52

STAT

JUNE 10, 2023

Chamber of Commerce sued the federal government over its new Medicare drug-price negotiation program on Friday, arguing that Congress tried to take too much power away from the courts. Merck, which makes a diabetes drug that could be subject to negotiation, sued on Tuesday.

Drug Pricing 222

Drug Pricing Diabetes 222

STAT

MARCH 6, 2023

WASHINGTON — Eli Lilly would’ve had to pay Medicaid about $150 for each vial of insulin used in the program if it hadn’t dramatically cut the list prices for some of its older products this week. The company was about to run into a Medicaid penalty for hiking the price of its drugs faster than the rate of inflation.

Biosimilars 239

Biosimilars Drug Pricing Diabetes 239

pharmaphorum

MAY 13, 2022

It has filed a lawsuit that accuses the drugmakers and pharmacy benefit managers Express Scripts, Caremark and OptumRx of conspiring to manipulate and inflate insulin prices in the state, inflating their profits and making the drugs unaffordable for many diabetics.

Diabetes 59

Diabetes Biosimilars Drug Pricing 59

Proxsys Rx

MARCH 23, 2023

The growing problem of prescription non-adherence According to a study published in the Annals of Internal Medicine, nearly 1/3 of all prescriptions are never filled by patients, and up to half of medications for chronic conditions like diabetes and hypertension are never taken.

Drug Pricing 52

Drug Pricing Prescription Filling Hospitals Dosage 52